Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis.
OBJECTIVE
Five cases of rhinocerebral mucormycosis (RCM) with different courses of illness and outcomes also due to different therapeutical strategies including Posaconazole as a new therapeutic option are described. Predisposing conditions for RCM are diabetes mellitus and immunosuppression. Diagnosis is often delayed because patients complain about nonspecific symptoms of acute rhinosinusitis, and initial CT imaging is unimpressive. Progressive disease, however, leads to early orbital and cerebral invasion. Due to the lack of typical clinical signs, diagnosis relies on histopathology. Therapy consists of the management of predisposing factors, radical surgical intervention and systemic antifungal therapy.


METHODS
We describe five cases of RCM with different comorbidities and outcomes.


RESULTS
RCM remains a diagnostic and therapeutic challenge because it begins with nonspecific symptoms and ends as fulminant disease with high mortality. Here, systemic treatment with Posaconazole appears to be a more effective alternative to amphotericin.


CONCLUSIONS
If a patient is suspected having RCM, improvement of predisposing diseases, radical surgical debridement and effective systemic antifungal therapy must be instituted immediately.
Scheckenbach
Kathrin
K
Department of Otorhinolaryngology, Head and Neck Surgery, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, Düsseldorf, Germany. scheckenbach@med.uni-duesseldorf.de
Cornely
Oliver
O
Hoffmann
Thomas K
TK
Engers
Rainer
R
Bier
Henning
H
Chaker
Adam
A
Greve
Jens
J
Schipper
Jörg
J
Wagenmann
Martin
M
D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D020806:Central Nervous System Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D006801:Humans; D008297:Male; D009091:Mucormycosis / Q000150:complications* / Q000188:drug therapy*; D012220:Rhinitis / Q000188:drug therapy* / Q000382:microbiology*; D012720:Severity of Illness Index; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole